Cargando…

Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma

Background: Hepatocellular carcinoma (HCC) accounts for more than 75% of primary liver cancers, which are the second leading cause of cancer-related deaths. The GALAD (gender, age, AFP-L3, AFP, and des-carboxy-prothrombin) score is a diagnostic tool developed based on gender, age, alpha-fetoprotein,...

Descripción completa

Detalles Bibliográficos
Autores principales: Cagnin, Silvia, Donghia, Rossella, Martini, Andrea, Pesole, Pasqua Letizia, Coletta, Sergio, Shahini, Endrit, Boninsegna, Giulia, Biasiolo, Alessandra, Pontisso, Patrizia, Giannelli, Gianluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671761/
https://www.ncbi.nlm.nih.gov/pubmed/38003675
http://dx.doi.org/10.3390/ijms242216485
_version_ 1785149455639511040
author Cagnin, Silvia
Donghia, Rossella
Martini, Andrea
Pesole, Pasqua Letizia
Coletta, Sergio
Shahini, Endrit
Boninsegna, Giulia
Biasiolo, Alessandra
Pontisso, Patrizia
Giannelli, Gianluigi
author_facet Cagnin, Silvia
Donghia, Rossella
Martini, Andrea
Pesole, Pasqua Letizia
Coletta, Sergio
Shahini, Endrit
Boninsegna, Giulia
Biasiolo, Alessandra
Pontisso, Patrizia
Giannelli, Gianluigi
author_sort Cagnin, Silvia
collection PubMed
description Background: Hepatocellular carcinoma (HCC) accounts for more than 75% of primary liver cancers, which are the second leading cause of cancer-related deaths. The GALAD (gender, age, AFP-L3, AFP, and des-carboxy-prothrombin) score is a diagnostic tool developed based on gender, age, alpha-fetoprotein, alpha-fetoprotein L3, and des-gamma-carboxy prothrombin, originally designed as a diagnostic tool for HCC in high-risk patients. Methods: We analyzed 212 patients with and without cirrhosis. The population study was divided into patients with liver cirrhosis without evidence of HCC at the time of serum sample collection for GALAD score determination and patients with liver cirrhosis and a confirmed diagnosis of HCC at the time of serum sample collection for GALAD score determination. Patients were followed up until death or liver transplantation. The association between variables and HCC mortality risk was performed, and the results were presented as hazard ratio (HR). The receiver operating characteristic (ROC) curve was used to assess the performance of the GALAD HCC diagnosis. The survival probability was explored using the non-parametric test, and the equality of survival amongst categories was assessed with the log-rank test. Results: Biomarkers were higher in the HCC group compared to cirrhosis. Kaplan–Meier survival probability analysis for individual GALAD categories revealed that a high GALAD level was associated with decreased survival during follow-up, and the difference between the curves was statistically significant (p = 0.01). Conclusions: Our findings suggest that the GALAD score has promise as a prognostic tool, with implications for improving patient management and treatment strategies for HCC.
format Online
Article
Text
id pubmed-10671761
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106717612023-11-18 Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma Cagnin, Silvia Donghia, Rossella Martini, Andrea Pesole, Pasqua Letizia Coletta, Sergio Shahini, Endrit Boninsegna, Giulia Biasiolo, Alessandra Pontisso, Patrizia Giannelli, Gianluigi Int J Mol Sci Article Background: Hepatocellular carcinoma (HCC) accounts for more than 75% of primary liver cancers, which are the second leading cause of cancer-related deaths. The GALAD (gender, age, AFP-L3, AFP, and des-carboxy-prothrombin) score is a diagnostic tool developed based on gender, age, alpha-fetoprotein, alpha-fetoprotein L3, and des-gamma-carboxy prothrombin, originally designed as a diagnostic tool for HCC in high-risk patients. Methods: We analyzed 212 patients with and without cirrhosis. The population study was divided into patients with liver cirrhosis without evidence of HCC at the time of serum sample collection for GALAD score determination and patients with liver cirrhosis and a confirmed diagnosis of HCC at the time of serum sample collection for GALAD score determination. Patients were followed up until death or liver transplantation. The association between variables and HCC mortality risk was performed, and the results were presented as hazard ratio (HR). The receiver operating characteristic (ROC) curve was used to assess the performance of the GALAD HCC diagnosis. The survival probability was explored using the non-parametric test, and the equality of survival amongst categories was assessed with the log-rank test. Results: Biomarkers were higher in the HCC group compared to cirrhosis. Kaplan–Meier survival probability analysis for individual GALAD categories revealed that a high GALAD level was associated with decreased survival during follow-up, and the difference between the curves was statistically significant (p = 0.01). Conclusions: Our findings suggest that the GALAD score has promise as a prognostic tool, with implications for improving patient management and treatment strategies for HCC. MDPI 2023-11-18 /pmc/articles/PMC10671761/ /pubmed/38003675 http://dx.doi.org/10.3390/ijms242216485 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cagnin, Silvia
Donghia, Rossella
Martini, Andrea
Pesole, Pasqua Letizia
Coletta, Sergio
Shahini, Endrit
Boninsegna, Giulia
Biasiolo, Alessandra
Pontisso, Patrizia
Giannelli, Gianluigi
Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma
title Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma
title_full Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma
title_fullStr Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma
title_full_unstemmed Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma
title_short Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma
title_sort galad score as a prognostic marker for patients with hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671761/
https://www.ncbi.nlm.nih.gov/pubmed/38003675
http://dx.doi.org/10.3390/ijms242216485
work_keys_str_mv AT cagninsilvia galadscoreasaprognosticmarkerforpatientswithhepatocellularcarcinoma
AT donghiarossella galadscoreasaprognosticmarkerforpatientswithhepatocellularcarcinoma
AT martiniandrea galadscoreasaprognosticmarkerforpatientswithhepatocellularcarcinoma
AT pesolepasqualetizia galadscoreasaprognosticmarkerforpatientswithhepatocellularcarcinoma
AT colettasergio galadscoreasaprognosticmarkerforpatientswithhepatocellularcarcinoma
AT shahiniendrit galadscoreasaprognosticmarkerforpatientswithhepatocellularcarcinoma
AT boninsegnagiulia galadscoreasaprognosticmarkerforpatientswithhepatocellularcarcinoma
AT biasioloalessandra galadscoreasaprognosticmarkerforpatientswithhepatocellularcarcinoma
AT pontissopatrizia galadscoreasaprognosticmarkerforpatientswithhepatocellularcarcinoma
AT giannelligianluigi galadscoreasaprognosticmarkerforpatientswithhepatocellularcarcinoma